Company intelligence / Profile preview

Corino Therapeutics

New York City, New York, United Statescorinorx.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Corino Therapeutics has developed CRX-1008, an oral small molecule TTR stabilizer. Clinical proof-of-concept studies have shown that CRX-1008 stabilizes TTR in both plasma and cerebrospinal fluid, with no drug-related adverse events or safety concerns reported. The company is preparing for Phase 2/3 trials targeting various forms of transthyretin amyloidosis

Therapeutic areas: NeurologyRare DiseasesCardiovascular
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

CRX-1008

Phase 2

Indications: ATTR-Cardiomyopathy, hATTR-Polyneuropathy, hATTR-Leptomeningeal

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of the latest available information.

Beyond the preview

Go deeper on Corino Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corino Therapeutics.

Explore the full profile